Thus, targeting PTBP2-BNIP3-mediated autophagy by genetic ablation of PTBP2 or pharmacological inhibition of PTBP2 can reduce the disease severity in the CML cells. The gene discussed is PTBP2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.